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Abstract
Background: Mitochondrial membrane protein‐associated neurodegeneration 
(MPAN) is caused by pathogenic sequence variants in C19orf12. Autosomal reces-
sive inheritance has been demonstrated. We present evidence of autosomal dominant 
MPAN and propose a mechanism to explain these cases.
Methods: Two large families with apparently dominant MPAN were investigated; 
additional singleton cases of MPAN were identified. Gene sequencing and multi-
plex ligation‐dependent probe amplification were used to characterize the causa-
tive sequence variants in C19orf12. Post‐mortem brain from affected subjects was 
examined.
Results: In two multi‐generation non‐consanguineous families, we identified dif-
ferent nonsense sequence variations in C19orf12 that segregate with the MPAN 
phenotype. Brain pathology was similar to that of autosomal recessive MPAN. We 
additionally identified a preponderance of cases with single heterozygous pathogenic 
sequence variants, including two with de novo changes.
Conclusions: We present three lines of clinical evidence to demonstrate that MPAN 
can manifest as a result of only one pathogenic C19orf12 sequence variant. We pro-
pose that truncated C19orf12 proteins, resulting from nonsense variants in the final 
exon in our autosomal dominant cohort, impair function of the normal protein pro-
duced from the non‐mutated allele via a dominant negative mechanism and cause loss 
of function. These findings impact the clinical diagnostic evaluation and counseling.
K E Y W O R D S
C19orf12, mitochondrial membrane protein‐associated neurodegeneration, MPAN, NBIA, 
neurodegeneration with brain iron accumulation
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1 |  INTRODUCTION
Neurodegeneration with brain iron accumulation (NBIA) 
comprises a group of inherited disorders that share the com-
mon feature of iron accumulation in the basal ganglia and 
present with a variety of neurologic and psychiatric mani-
festations (Gregory & Hayflick, 2013). The genetic bases 
of most NBIA disorders are now known (Meyer, Kurian, 
& Hayflick, 2015). C19orf12 pathogenic sequence variants 
cause mitochondrial membrane protein‐associated neurode-
generation (MPAN [MIM: 614298]) (Hartig et al., 2011). 
MPAN typically presents in childhood or adolescence with 
progressive dystonia‐parkinsonism, optic atrophy, axonal 
motor neuronopathy, and iron deposition in globus pallidus 
(GP) and substantia nigra (SN) (Hartig et al., 2011; Hogarth 
et al., 2013). An autosomal recessive pattern of inheritance 
has been demonstrated in well‐characterized cases of MPAN 
(Hartig et al., 2011; Hogarth et al., 2013). A common Polish 
founder deletion, often seen in a homozygous state in Eastern 
European families, accounts for many published cases of 
MPAN, though numerous other deleterious mutations have 
now also been documented (Gagliardi et al., 2015; Hartig et 
al., 2011; Hartig, Prokisch, Meitinger, & Klopstock, 2013).
We have observed a large number of typical MPAN cases 
with heterozygous pathogenic sequence variants identified in 
C19orf12 in our large International Registry of NBIA and 
Related Disorders. Recent ascertainment of two multi‐gen-
eration families with MPAN and a heterozygous C19orf12 
pathogenic sequence variant segregating in an autosomal 
dominant pattern suggests that a single mutant allele is suffi-
cient to cause the MPAN phenotype in specific cases. In two 
additional families, identification of heterozygous de novo 
pathogenic sequence variants causing MPAN lends further 
support to this concept. De novo pathogenic dominant vari-
ants in C19orf12 may account for the preponderance of het-
erozygous cases in our repository.
2 |  MATERIALS AND METHODS
2.1 | Ethical compliance
All subjects were consented as part of OHSU's IRB‐approved 
protocol e7232 with additional work covered by protocol 
e144 (conforming to the US Federal Policy for the Protection 
of Human Subjects).
2.2 | Subjects
Individuals presented are subjects in the OHSU International 
NBIA Repository, a database and sample repository of more 
than 800 families established 28 years ago. The proband from 
Family 18 was originally submitted to the repository by the 
Parkinson's Disease Center and Movement Disorders Clinic 
(PDCMDC) at Baylor College of Medicine, Houston, Texas in 
1995. Family 18 has been investigated periodically since that 
time, and medical records and samples have been collected 
when possible. Subject 18‐307 was evaluated in the PDCMDC, 
and subject 18‐411 was evaluated in the PDCMDC and sepa-
rately on a research basis by the OHSU team. Family 748 was 
originally ascertained through the Department of Neurology, 
University of Rochester Medical Center, New York. In addition, 
the repository was queried for all subjects with single heterozy-
gous C19orf12 sequence variants. For some cases, clinical mo-
lecular genetic testing results were also banked in the repository.
2.3 | Sequencing
Genomic DNA was extracted from blood, saliva, or estab-
lished cell lines, and C19orf12 exons 1–3 (NM_001031726.3) 
were amplified by PCR. Products were sequenced at the 
Vollum DNA Sequencing Core at OHSU, and variants were 
identified on chromatograms. In some cases, commercial 
exome sequencing was performed for clinical purposes and 
obviated research sequencing.
2.4 | Multiplex ligation‐dependent probe 
amplification
A total of five C19orf12‐specific probes targeting the promoter 
(n = 1), the coding exons (n = 2), the 3’UTR (n = 1), and a 
region approximately 1 Kb downstream of the gene (n = 1) 
were utilized for multiplex ligation‐dependent probe ampli-
fication (MLPA) analysis by the Beetz Lab (Dept of Clinical 
Chemistry, Jena University Hospital, Germany). Five reference 
probes were directed against regions on distinct other chromo-
somes. MLPA probe design followed the guidelines provided 
by MRC‐Holland (The Netherlands) at www.mlpa.com. The 
corresponding synthetic oligonucleotides were purchased from 
MWG‐Eurofins (Ebersberg, Germany). MLPA reactions uti-
lized reagents from MRC‐Holland. Analysis of data was done 
as described previously (Beetz et al., 2006).
2.5 | Analysis of postmortem brain tissue
Autopsy and neuropathologic evaluation of two subjects 
(18‐306 and 748‐301) were performed as previously de-
scribed for a case of recessive MPAN (Hogarth et al., 2013). 
In brief, brain tissue was immersed in 10% neutral buffered 
formalin for at least 10 days, followed by dissection into sec-
tions containing the midbrain, frontal cortex, hippocampus 
and basal ganglia. Sections were embedded in paraffin and 
cut into 6‐micron sections using standard methods. Sections 
were stained with hematoxylin and eosin, and immunohis-
tochemistry with antibodies to alpha‐synuclein (LB509, 
Thermo Scientific, Rockord, IL), tau (PHF‐1, a kind gift of 
Dr. Peter Davies, Albert Einstein University of Medicine, 
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Manhasset, NY), beta‐amyloid (4G8, BioLegend, San Diego, 
CA), ubiquitin, and TDP‐43 (Proteintech Group, Rosemont, 
IL) was performed after deparaffinization and prepared for 
antigen retrieval by 95% formic acid for 5 min and 30 min in 
citrate buffer (pH 6.0 at 90°C). Tissue sections were blocked 
with 5% nonfat dry milk in phosphate‐buffered saline and 
incubated with antibodies at concentrations recommended 
by the suppliers followed by color development using 
diaminobenzidine.
3 |  RESULTS
3.1 | Evaluation of family 18
The proband, a 39‐year‐old woman (18‐307, Figure 1) pre-
sented to the PDCMDC with an 18‐month history of neu-
rologic symptoms. On examination, she had hypomimia, 
hypophonia, and left‐sided predominant parkinsonism 
with rigidity and bradykinesia. Magnetic resonance imag-
ing (MRI) revealed markedly decreased signal in GP and 
F I G U R E  1  Pedigrees. Family 18: According to report by living family members, individuals 101, 102, and 202 all died in their sixties from 
health issues unrelated to MPAN; they were not reported to have an MPAN phenotype or signs of parkinsonism prior to their deaths. Individual 205 
is 81 years and reports being in good health for his age with no signs of MPAN or parkinsonism. Family 748: Individuals 101, 102 and 201 were all 
reported to have had early dementia. MPAN, membrane protein‐associated neurodegeneration
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SN bilaterally on T2‐weighted images, consistent with 
brain iron accumulation. The autopsy, performed at age 
42 in 1998, showed rusty brown discoloration of the GP 
and SN. Microscopic examination revealed perivascular 
iron pigment deposition in the GP, gliosis, and promi-
nent, ubiquitin‐positive axonal spheroids. The SN showed 
reduced number of cells, gliosis, axonal spheroids and 
Lewy bodies. Axonal spheroids were also present in the 
hippocampus and cerebellum. Her autopsy diagnosis was 
“Hallervorden‐Spatz disease.” The case was submitted 
to the OHSU repository. After initial improvement with 
dopaminergic medications, her parkinsonism markedly 
worsened over two years with development of psychosis. 
She died in hospice at the age of 42 years. At the time of 
ascertainment, she reported an extended history of similar 
disease in several family members suggesting of an auto-
somal dominant pattern.
The brother of the proband (18‐304, Figure 1) was pub-
lished in a 1989 case report that suggested the family's dis-
ease, then called Hallervorden‐Spatz syndrome, could be the 
first autosomal dominant instance of the disorder (Morphy, 
Feldman, & Kilburn, 1989). He had progressive parkinson-
ism, depression, and dementia; no MRI was performed. At 
that time, two paternal aunts and a paternal uncle had died 
after similar courses, and one of the cases was confirmed by 
autopsy (Morphy et al., 1989). The subject died after a rapid, 
8‐month decline from pulmonary edema just before his 34th 
birthday.
Subject 18‐411 (Figure 1, Video S1), a 34 year‐old pre-
viously healthy employed male who was also a competitive 
athlete, presented in 2016 with a one‐year history of gait 
imbalance. His symptoms progressed rapidly to marked 
motor slowness and shuffling gait, tremors in both arms, and 
anxiety. Neurological examination showed hypomimia, hy-
pokinetic dysarthria and hypophonia, moderate right‐sided 
predominant bradykinesia and rigidity, bilateral postural 
and kinetic hand tremor, decreased right arm swing, stooped 
posture and shuffling gait. MRI of his brain revealed T2 
hypointense signal in the GP, with isointense signal at the 
medial medullary lamina (Figure 2). The DaT scan was con-
sistent with parkinsonism with reduced dopamine transporter 
uptake in the striatum. His parkinsonism improved markedly 
after initial trial of levodopa (Video S1) but he soon devel-
oped levodopa‐related motor fluctuations and dyskinesia. At 
the time of presentation, the subject reported a family his-
tory that we recognized as that of Family 18 from the OHSU 
repository. He was subsequently identified as a first cousin 
once removed to 18‐307. Updates to the family history re-
vealed additional affected individuals. His mother (18‐310) 
was examined and did not have any clinical features concern-
ing for dystonia or parkinsonism.
Subject 18‐306, a sibling to the proband, died from com-
plications of MPAN at 65 years of age. He had mild cognitive 
changes starting at 55 years that progressed to dementia with 
parkinsonism.
Subject 18‐403, the daughter of individual 18‐304, died 
at 42 years of age. She developed depression at 19 years but 
was otherwise stable until 38. At that time, she developed gait 
changes and cognitive decline, followed by urinary inconti-
nence and inability to perform activities of daily living.
Overall, nine affected individuals from three generations 
have been identified in family 18. Shortly after publication 
of the C19orf12 gene and associated phenotype3, the pro-
band's sample was sequenced on a research basis at OHSU 
and a novel heterozygous 11 base‐pair deletion was detected: 
c.227_237del (p. Met76Thrfs*3). Although the sequence 
variant caused a frameshift/premature stop in the protein and 
was predicted to be pathogenic, MPAN had only recently 
been described and was reported as an autosomal recessive 
disorder. At that time, it was considered most likely that she 
was a carrier of a recessive C19orf12 variant that could not, 
in isolation, explain her disease. In the three additional af-
fected individuals from whom we were subsequently able to 
collect samples, the C19orf12 sequence variant was found to 
segregate with disease (Figure 1). Subject 18‐205 (80 years of 
age), the only surviving and healthy sibling from the first af-
fected generation, also harbors the sequence variant. Neither 
his children nor his grandchildren are reported to have any 
clinical signs of MPAN. Similarly, neither 18‐101 nor 18‐102 
were reported to have symptoms prior to their deaths. In clin-
ically affected individuals, onset ranges from 29 to 56 years.
3.2 | Evaluation of family 748
The proband (748‐402, Figure 1) is a 32  year‐old female 
with parkinsonism and progressive neurocognitive decline 
that started in her late 20s following a first trimester miscar-
riage. The patient noted mood changes and fatigue and was 
diagnosed with depression. This was followed by worsening 
gait instability, slowed movements, difficulty with fine motor 
skills, and then debilitating pseudobulbar affect and urinary 
incontinence. Her exam initially showed rigidity, spasticity, 
bradykinesia, postural instability, marked hyperreflexia, and 
extensor toe sign bilaterally. She developed tremor approxi-
mately a year after her initial cognitive decline. Carbidopa/
levodopa lessened her rigidity, bradykinesia, and tremor. 
Her brain MRI showed iron accumulation in the GP and SN. 
Genetic testing identified a maternally inherited heterozy-
gous C19orf12 pathogenic sequence variant (c.336G>A, 
p.W112*).
Her mother (748‐301, Figure 1) developed personal-
ity changes, slowed movements, and cognitive decline in 
her 30’s, after the birth of her fourth child. At 55 years she 
had worsening dementia and parkinsonism. A brain MRI 
done several years earlier had shown basal ganglia iron ac-
cumulation. Genetic testing confirmed that she harbored 
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the heterozygous variant found in her daughter. She died at 
age 59 years, and her family donated her brain for research 
studies. The family reported similar histories of early‐onset 
dementia and progressive disease in the proband's maternal 
grandmother (748‐201), great‐grandmother (748‐102) and 
sister of her great‐grandmother (748‐101).
3.3 | Additional cases with heterozygous 
pathogenic sequence variants in C19orf12
Since the initial identification of C19orf12, the OHSU 
International NBIA Repository has collected cases of MPAN. 
In total, there are 18 heterozygous cases from 13 families 
(Table 1) and 22 homozygous or compound heterozygous 
cases from 19 families (Table 2) entered in the repository. 
Only C19orf12 exons and intron borders were analyzed, 
therefore deep intronic pathogenic sequence variants were 
not expected to be detected. Additional testing for deletions 
and duplications by MLPA failed to identify a second muta-
tion in any of the heterozygous families. None of the parents 
of heterozygous singleton cases have manifest MPAN or re-
lated features. Affected siblings from family 691 share the 
same copy of the nonsense variant c.238C>T. These siblings 
were adopted, and parental disease status is unknown.
Subjects with a heterozygous variant show clinical and 
MRI features (Figure 2) that are consistent with MPAN, and 
most have a phenotype that is indistinguishable from that of 
cases with two variants. Of note, subjects 661 and 698 were 
tested clinically as trios with their parents by exome sequenc-
ing, which revealed single de novo pathogenic sequence vari-
ants in the proband. In most other cases from the repository, 
parental DNA was not available.
3.4 | Neuropathologic findings
Histologic evaluation of brain tissue from an individual 
from each of the two autosomal dominant families (18‐306 
and 748‐301) revealed the key features previously found in 
recessive MPAN, including iron accumulation in the GP 
with profound neuronal loss, gliosis, axonal spheroids and 
degenerating neurons (Hartig et al., 2011; Hogarth et al., 
2013). As in recessive disease, alpha‐synuclein staining 
was positive throughout with midbrain, limbic, and neocor-
tical Lewy bodies and neurites in subjects with heterozy-
gous variants. Tauopathy was limited, with pretangles and 
few neurofibrillary tangles, chiefly in the CA1 sector of the 
hippocampus. Beta‐amyloid plaques and TDP‐43‐positive 
inclusions were not found. No features unique to heterozy-
gous disease were evident based on pathology previously 
reported in recessive cases (Hartig et al., 2011; Hogarth et 
al., 2013).
4 |  DISCUSSION
4.1 | MPAN can be dominant or recessive
To date, MPAN has been documented to follow an autosomal 
recessive pattern of inheritance, except in a few suspect cases 
(Monfrini et al., 2018). We provide three lines of evidence 
that suggest MPAN can also be caused by a heterozygous 
pathogenic sequence variant in C19orf12 on the basis of: 1) 
dominant inheritance exhibited by Family 18 and Family 
748; 2) the manifestation of classic MPAN in 2 cases with de 
novo single mutations; and 3) a preponderance of heterozy-
gous cases in our cohort with frameshift/premature stop or 
nonsense variants all clustering in the last exon. Recessive 
and dominant MPAN are clinically indistinguishable, with 
rare exceptions.
In family 748, a single pathogenic variant segre-
gates with disease from parent to child, and two earlier 
F I G U R E  2  MRI findings in dominant MPAN. T2‐weighted 
imaging of brain at the level of the globus pallidus (axial left; coronal 
right) showing hypointense signal indicative of iron accumulation in 
subject 18‐411 (panel a, presumed dominant case) and subject 248 
(panel b, recessive case). Characteristic of MPAN and seen in both 
cases is the preservation of isointense signal in the medial medullary 
lamina, which localizes between the globus pallidus interna and 
externa. MPAN, membrane protein‐associated neurodegeneration; 
MRI, Magnetic resonance imaging
(a)
(b)
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generations were well‐documented to be similarly affected. 
In family 18, a single C19orf12 sequence variant segre-
gates with disease through three generations. Incomplete 
penetrance and variable expressivity are common phenom-
ena in autosomal dominant single‐gene disorders and may 
explain the lack of symptoms in some individuals, includ-
ing 18‐310, a presumed obligate carrier, as well as 18‐205 
(Figure 1). This possibility invites caution in associating 
genotype with phenotype in dominant MPAN and will 
impact clinical care. In two additional families (661, 698, 
Table 1), we have reported the presence of a heterozygous 
de novo pathogenic sequence variant in the probands, a 
common observation in dominant disorders. Though we do 
not currently have parental DNA from the remaining het-
erozygous cases, we predict that most or all mutations in 
the remaining singletons are in fact de novo.
T A B L E  1  Heterozygous cases from the OHSU International NBIA Repository
Subject Gene mutation Protein alteration Mutation type
Del/dup 
testing
Age at 
onset Major features
18‐306 c.227_237del11 p.Met76Thrfs*3 Frameshift‐ 
premature stop
Not tested (18‐411 
negative)
55 years Cognitive decline, parkinsonism
18‐307 c.227_237del11 p.Met76Thrfs*3 Frameshift‐ 
premature stop
Not tested (18‐411 
negative)
37 years Neuropsychiatric changes, pro-
gressive parkinsonism
18‐403 c.227_237del11 p.Met76Thrfs*3 Frameshift‐ 
premature stop
Not tested (18‐411 
negative)
19 years Neuropsychiatric changes, gait 
change, cognitive decline
18‐411 c.227_237del11 p.Met76Thrfs*3 Frameshift‐ 
premature stop
Negative 34 years Gait imbalance, motor slowness, 
tremor, anxiety, progressive 
parkinsonism
220 c.278delC p.Pro93Leufs*26 Frameshift‐ 
premature stop
Negative 18 years Optic atrophy, progressive par-
kinsonism, cognitive decline
227 c.256C>T p.Gln86* Nonsense Negative 12 years Gait changes, wheelchair at 
18 years, optic atrophy, cogni-
tive decline
392 c.278dupC p.Pro93Profs*8 Frameshift‐ 
premature stop
Negative 9 years Cognitive decline, optic atrophy, 
dystonia and dysarthria
437 c.357dupG p.Ala120Glyfs*32 Frameshift‐ 
premature stop
Negative 29 years Neuropsychiatric changes, par-
kinsonism, cognitive decline
474 c.279delT p.Ala94Profs*25 Frameshift‐ 
premature stop
Negative 9 years Falling, poor school performance, 
dysarthria
630 c.300delT p.Phe100Leufs*19 Frameshift‐ 
premature stop
Negative 5 years Gait changes, optic atrophy, spas-
tic paraparesis, cognitive decline
655 c.268G>T p.Glu90* Nonsense Negative 22 years Gait changes, depression, mild 
dystonia and dysarthria
661 c.279_282del 
TGCC de 
novo
p.Ala94Serfs*24 Frameshift‐ 
premature stop
Negative 4 years Developmental delay, spastic-
ity, dystonia, disinhibited 
personality
663 c.349C>T p.Gln117* Nonsense Negative 18 months Dystonia, lower limb spasticity, 
sensorineural hearing loss
691‐1 c.238C>T p.Gln80* Nonsense Negative 10 years Progressive spastic tetraparesis, 
optic disc pallor, dysphagia
691‐2 c.238C>T p.Gln80* Nonsense Negative 10 years Progressive spastic tetraparesis, 
cognitive decline, optic disc 
pallor
698 c.238C>T 
de novo
p.Gln80* Nonsense Negative 5 years Gait disturbance, optic atrophy, 
neuropsychiatric symptoms
748‐301 c.336G>A p.Trp112* Nonsense Not tested (748‐402 
negative)
30 years Neuropsychiatric symptoms, 
parkinsonism, dementia
748‐402 c.336G>A p.Trp112* Nonsense Negative 28 years Cognitive decline, parkinsonism, 
dysarthria
Note: Del/dup testing = testing for deletions and duplications by multiplex ligation‐dependent probe amplification (MLPA).
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T A B L E  2  Homozygous/ compound heterozygous cases from the OHSU International NBIA Repository
Subject Gene mutation Protein alteration Mutation type
Del/dup 
testing
Age at 
onset Major features
76 c.116C>T 
c.205G>A
p.Ser39Phe 
p.Gly69Arg
Missense 
Missense
N/A 11 years Gait changes, cognitive decline, 
dystonia
160 c.204_211del11 
(homozygous)
p.Gly69Argfs*10 Frameshift‐ 
premature stop
Negative 10 years Tremor, cognitive decline, spastic 
tetraparesis, optic atrophy
165 c.204_211del11 
c.157G>A
p.Gly69Argfs*10 
p.Gly53Arg
Frameshift‐ 
premature stop; 
missense
N/A 10 years Gait change, spasticity, optic atrophy
195 c.248C>T 
c.400G>C
p.Pro83Leu 
p.Ala134Pro
Missense; 
missense
N/A 10 years Optic atrophy, spasticity, parkinson-
ism, cognitive decline
196 c.204_211del11 
c.294G>C
p.Gly69Argfs*10 
p.Arg98Ser
Frameshift‐ 
premature stop; 
missense
N/A 29 years Cognitive decline, expressive dyspha-
sia, parkinsonism
248 c.204_211del11 
c.205G>A
p.Gly69Argfs*10 
p.Gly69Arg
Frameshift‐ 
premature stop; 
missense
N/A 9 Dysarthria, gait change, dystonia, 
parkinsonism, incontinence, cogni-
tive decline
251‐1 c.194delG 
(homozygous)
p.A67Lfs*6 Nonsense Negative 13 years Gait changes, cognitive decline, 
incontinance
251‐2 c.194delG 
(homozygous)
p.A67Lfs*6 Nonsense 251‐1 
negative
13 years Gait changes, cognitive decline, 
dysarthria
281‐1 c.142G>C 
c.194−2A>G
p.Ala48Pro 
p.?
Missense; 
splice site
N/A 10 years Progressive spasticity, parkinsonism, 
cognitive decline
281‐2 c.142G>C 
c.194−2A>>G
p.Ala48Pro 
p.?
Missense; 
splice site
N/A 10 years Developmental delay, spasticity, gait 
changes
334 c.157G>A 
c.205G>A
p.Gly53Arg 
p.Gly69Arg
Missense; 
missense
N/A 8 years Progressive spasticity, mild intention 
tremor, gait changes
341 c.194G>A 
(homozygous)
p.Gly65Glu Missense Negative 4 years Psychosis, dystonia, tremor
348 c.194G>T 
c.179C>T
p.Gly65Val 
p.Pro60Leu
Missense; 
missense
N/A 4 years Spastic paraparesis, dysarthria, devel-
opmental delay
379 c.194G>T 
(homozygous)
p.Gly65Val Missense Negative 6 years Optic atrophy, spasticity, cognitive 
decline
396 c.204_211del11 
(homozygous)
p.Gly69ArgfsX10 Frameshift‐ 
premature stop
Negative 3 years Dystonia, neuropsychiatric changes, 
cognitive decline, intention tremor
433 c.194G>A 
c.400G>C
p.Gly65Glu 
p.Ala134Pro
Missense; 
missense
N/A 9 years Spasticity, optic atrophy, cognitive 
decline
438 c.204_211del11 
(homozygous)
p.Gly69Argfs*10 Frameshift‐ 
premature stop
Negative 6 years Spastic paraparesis, optic atrophy, 
dystonia, parkinsonism, cognitive 
decline
440 c.171_181del11 
(homozygous)
p.Gly58Argfs*10 Frameshift‐ 
premature 
stop
Negative 14 years Dysarthria, dystonia, incontinence, 
neuropsychiatric changes
446‐1 c.194G>T 
c.204_214del11
p.Gly65Val 
p.Gly69Argfs*10
Missense; 
frameshift‐ 
premature stop
N/A 13 years Progressive spasticity and motor 
decline, optic atrophy, significant 
neuropsychiatric changes, cognitive 
decline
446‐2 c.194G>T 
c.204_214del11
p.Gly65Val 
p.Gly69Argfs*10
Missense; 
frameshift‐ 
premature stop
N/A 11 years Progressive lower extremity spastic-
ity, upper extremity weakness, optic 
atrophy, cognitive decline
(Continued)
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Independent of inheritance pattern, most MPAN cases are 
phenotypically similar. The disease manifests chiefly with 
gait abnormality, dystonia, dysarthria, spasticity, optic atro-
phy, rapidly progressive parkinsonism, cognitive decline, and 
psychosis. Parkinsonism initially improves with levodopa, 
but levodopa‐related motor fluctuations and dyskinesias are 
followed by gradual loss of efficacy. Correspondingly, patho-
logic features that were described in recessive MPAN are re-
capitulated in dominant disease.
Numerous examples exist of disorders caused by patho-
genic sequence variants in one gene leading to different 
patterns of inheritance (Ben‐Shachar et al., 2009; Koch et 
al., 1992; Monreal et al., 1999). However, most such cases 
comprise phenotypically distinct disorders that were not sus-
pected to be allelic.
4.2 | Genotype determines 
inheritance pattern
In single‐gene disorders, mutation type and location in-
fluence the mechanism of disease and thus the pattern of 
inheritance. Some mutations cause loss‐of‐function and 
others gain‐of‐function. Nonsense mutations, depend-
ing on their locations within a gene, can lead to produc-
tion of stable or unstable truncated protein or no protein. 
Nonsense‐mediated decay (NMD) is the cellular surveil-
lance system to detect and destroy mRNA transcripts that 
contain a premature stop codon. But such mutations are 
detected only when they are located within or upstream (5′) 
of the penultimate exon; those occurring in the final exon 
or within ~50 nucleotides of the 3′ end of the penultimate 
exon typically escape NMD (Lewis, Green, & Brenner, 
2003). We propose a plausible hypothesis for the different 
patterns of inheritance in MPAN based on mutation type 
and location within the gene.
4.3 | Recessive MPAN
In autosomal recessive MPAN, a nonsense mutation occur-
ring in the first or second exon would be predicted to undergo 
NMD, producing no protein and causing loss‐of‐function. From 
parental studies of recessive MPAN, we know that partial loss‐
of‐function from one nonsense C19orf12 allele causes no ap-
parent neurologic problems in these carriers. Instead, two such 
mutant alleles are required to cause a complete loss‐of‐function 
in order to manifest disease, as we observe in our recessive co-
hort (Figure 3). The homozygous and compound heterozygous 
cases presented in Table 2 and Figure 3 comprise a mix of non-
sense mutations predicted to undergo NMD, as well as mis-
sense and splice‐site mutations localized throughout the gene 
and predicted to cause loss‐of‐function.
4.4 | Dominant MPAN
In contrast, 13 proposed dominant families have heterozygous 
nonsense variants located in the last exon (Figure 3), and all are 
predicted to escape NMD and produce a truncated protein. Such 
a mutant product could lead to disease via one of two mecha-
nisms: the mutant protein could exhibit a toxic gain‐of‐func-
tion or it could interfere with the function of the normal protein 
produced from the wildtype allele, a mechanism characterized 
as dominant‐negative. Both of these mechanisms require only 
a heterozygous mutant allele to cause disease and would there-
fore demonstrate dominant inheritance.
4.5 | Proposed dominant‐
negative mechanism
Our clinical observations inform our hypothesis about the 
specific disease mechanism causing dominant MPAN. 
Recessive MPAN, caused by C19orf12 loss‐of‐function, is 
phenotypically similar to that of dominant MPAN. A toxic 
gain‐of‐function would be unlikely to lead to a disease phe-
notype that is indistinguishable from one arising from loss‐
of‐function, but a dominant‐negative mechanism would 
ultimately cause loss‐of‐function, as in recessive disease. 
Based on our phenotype and genotype data, we propose a 
dominant‐negative mechanism in which the mutant protein 
interferes with the function of the normal protein encoded by 
the wild‐type allele, causing its loss‐of‐function.
Proteins that homo‐multimerize, such as collagen, com-
monly demonstrate a dominant‐negative disease mechanism 
Subject Gene mutation Protein alteration Mutation type
Del/dup 
testing
Age at 
onset Major features
447 c.94delA 
c.248C>T
p.Met32fs* 
p.Pro83Leu
Nonsense; missense N/A 10 years Gait change, optic atrophy, spasticity, 
dystonia, cognitive decline
629 c.205G>A 
(homozygous)
p.Gly69Arg Missense Negative 7 years Developmental delay, gait change, 
progressive dysarthria, dysphagia 
and spasticity
Note: Del/dup testing = testing for deletions and duplications by multiplex ligation‐dependent probe amplification (MLPA).
N/A = no indication to do del/dup testing because two pathogenic sequence variants were identified by other methods.
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resulting from a single pathogenic sequence variant. Based 
on these observations, we suggest that the C19orf12 protein 
functions as a homo‐multimer. Further evidence in support 
of this hypothesis is the presence of a functional region in 
C19orf12 that contains a glycine‐zipper motif, which is 
commonly found in proteins that are known to multimerize 
(Gagliardi et al., 2015). Truncated C19orf12 protein variants 
that retain a putative interacting domain might preserve the 
ability to multimerize with protein from the wildtype allele 
yet still damage the function of the protein complex or induce 
degradation as a complex. In such cases, the final outcome is 
loss‐of‐function.
We considered haploinsufficiency as an alternate domi-
nant disease mechanism. The location of the initiation codon 
methionine in several shorter transcripts (NM_001282929.1, 
NM_001282930.1, and NM_001282931.1) is striking, and 
raises the possibility of haploinsufficiency. The cluster-
ing of truncating variants, defined by the most N‐terminal 
of those described (p.Met76Thrfs*3 in the longer transcript 
NM_00103176.3 in Family 18) at the equivalent position of 
Met1 in the shorter transcripts, may represent the loss of pro-
tein products that perform a role in the same pathway or com-
plexes as those encoded by the longer transcripts, but which 
are more sensitive to changes in protein abundance.
Five recessive families (165, 196, 248, 396, and 438, 
Figure 3) harbor a nonsense variant that is predicted to 
truncate the protein at the same codon as that occurring in 
dominant Family 18. All five of these families have a second 
pathogenic sequence variant, and none of the carrier parents 
shows features of MPAN. The difference between the pre-
dicted protein produced by the recessive truncation at codon 
79 versus that from the dominant truncation also at codon 79 
is the identity of the terminal nine amino acids. This observa-
tion suggests that the normal amino acid sequence of residues 
69–76 may be necessary and sufficient for homo‐multim-
erization of the C19orf12 protein. Such information may in-
form mutation interpretation and pattern of inheritance.
4.6 | Future directions
Functional studies are required to explore the mechanisms 
proposed here, including analysis of mRNA expression 
for NMD and the level of C19orf12 protein expression. 
Moreover, it will be crucial to explore whether dominant 
versus recessive pathogenic sequence variants differentially 
affect the protein‐protein interaction in order to understand 
the disease mechanism. Regardless, the autosomal dominant 
pedigrees, de novo cases, and clustering of similar pathogenic 
F I G U R E  3  C19orf12 mutation types. A schematic of the C19orf12 gene with heterozygous and homozygous pathogenic sequence variants 
identified for all families studied. Mutant protein changes are listed first (nucleotide data are in Tables 1 and 2), followed by family numbers 
with each change. Single pathogenic sequence variant (dominant) cases are labeled in bold above the schematic diagram of the gene; two‐variant 
(recessive) cases are below
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sequence variants in the heterozygous cohort provide suffi-
cient evidence to support a dominant mechanism and to im-
pact clinical care recommendations.
4.7 | Implications for patient care
Our results directly impact clinical care of people known 
or suspected to have MPAN. When a single variant al-
lele is identified in an individual with clinical features of 
MPAN, the clinician must consider autosomal dominant 
MPAN in the differential diagnosis. Our data reveal that 
genotype often predicts the sufficiency of a single muta-
tion to cause disease; all dominant pathogenic sequence 
variants lead to a protein that is truncated after amino acid 
79, with wild‐type residues 69–76 intact. As a corollary, 
none of the recessive sequence variants produces a protein 
that terminates after amino acid 79. Therefore, the precise 
nature and location of a sequence variant in C19orf12 ena-
bles prediction of its sufficiency to cause disease as a het-
erozygous allele.
Predictive testing may be possible in individuals with 
a family pathogenic sequence variant but without disease 
signs or symptoms; however, interpretation of genetic 
data may be complicated by multiple factors, including 
incomplete penetrance and variable expressivity. Parental 
testing is recommended in all cases with one or two vari-
ants in order to determine phase (cis or trans) and identify 
whether a heterozygous C19orf12 sequence variant in the 
proband is de novo, implicating it as likely pathogenic. 
Such testing will also inform recurrence risk, though go-
nadal mosaicism remains a possibility. Given that MPAN 
can present during adulthood, there may be significant 
reproductive implications for affected individuals with 
dominant disease, and their children may be at risk for 
MPAN. As we learn more about the function of the 
C19orf12 protein, new insights into disease pathogenesis 
will improve our care of people affected by this disorder 
of NBIA.
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